

Special Issue

MicroRNAs in Precision Medicine: Regulation, Biomarkers and Novel Therapeutics

Message from the Guest Editor

MicroRNAs (miRNAs) are pivotal regulators of gene expression, cellular development, and disease pathogenesis. This Special Issue, titled “New Advances in MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in Diseases,” aims to compile cutting-edge research that explores the multifaceted roles of miRNAs in various diseases, from cancer and cardiovascular disorders to neurodegenerative and infectious diseases. Key topics include the regulatory mechanisms of miRNAs in cellular pathways, their potential as biomarkers for early disease detection, and innovative therapeutic strategies targeting miRNAs. Recent advancements in omics technologies and bioinformatics have significantly enhanced our understanding of miRNA functions and their interactions with other cellular components. These insights are crucial for developing novel diagnostic tools and therapeutic interventions. We invite original research and reviews on miRNA roles in disease mechanisms, biomarker applications, and miRNA-based therapies. By integrating multidisciplinary approaches, this issue aims to advance miRNA research and its clinical translation.

Guest Editor

Dr. Shing Cheng Tan

UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia

Deadline for manuscript submissions

31 December 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/246253

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).